Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated medical claim is directly supported by the provided FDA label excerpts (contraindication in pregnancy, embryo-fetal toxicity warning, pregnancy verification/reassessment for monthly 6-month RVVC use, and contraception through 4 days after last dose). No contradictions or off-label promotion are evident in the provided response.
Category Scores
Accurate Statements
BREXAFEMME is contraindicated in pregnancy due to risk of embryo-fetal toxicity/fetal harm.
Contraindications (Section 4); Risk of Embryo-Fetal Toxicity (Section 5.1); Pregnancy (Section 8.1).
Pregnancy testing/verification prior to initiating treatment is required for females of reproductive potential.
Risk of Embryo-Fetal Toxicity (Section 5.1) and Pregnancy Evaluation Prior to Initiating Treatment (Section 2.3).
Reassessment of pregnancy status prior to each dose is recommended when used monthly for 6 months for reduction in the incidence of RVVC.
Risk of Embryo-Fetal Toxicity (Section 5.1) and Pregnancy Evaluation Prior to Initiating Treatment (Section 2.3).
Effective contraception is required during treatment and for 4 days after the last dose (as stated for VVC treatment and for RVVC prevention over the 6-month period plus 4 days after the last dose).
Risk of Embryo-Fetal Toxicity (Section 5.1) and Females and Males of Reproductive Potential (Section 8.3).
Unsupported Statements
Contradictions
Important Omissions
No additional label elements (e.g., hypersensitivity contraindication, animal malformation details, or pregnancy safety study reporting instructions) were mentioned in the evaluated medical claim; however, these omissions are not necessary to support the specific pregnancy-related contraindication/testing/contraception claim presented.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response focuses on pregnancy-related contraindication and label-mandated pregnancy evaluation and contraception duration, which are directly supported by the provided prescribing information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement